Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities
- 22 July 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18665-18691
Abstract
Sustained activation of endosomal Toll-like receptors (TLR) 7, 8, and 9 by self-nucleic acids is considered to be a key driver for autoimmune diseases, e.g., systemic lupus erythematosus (SLE). We report the discovery of a novel series of potent, orally bioavailable TLR7/8/9 triple antagonists featuring a unique “N-aryl-N” pharmacophore. Guided by TLR8 cocrystal structures and TLR7/9 homology models, we systematically optimized the series to balance pan-TLR potency with drug-like properties. Strategic modulation of lipophilicity and basicity successfully reduced the high volume of distribution (Vss) observed in mouse for early leads. Further compound optimization eliminated a reactive metabolite (GSH) liability. The resulting lead, compound 41, demonstrated robust dose-dependent inhibition of TLR7 and TLR9 pathways in mouse challenging models, supporting the potential of a TLR7/8/9 triple antagonist for treating autoimmune diseases.Keywords
Funding Information
- Roche (NA)
This publication has 33 references indexed in Scilit:
- Structure-guided approaches to modulate endosomal toll-like receptors TLR7, TLR8 and TLR9: advances, challenges and therapeutic promiseDrug Discovery Today, 2025
- Current developments in Coot for macromolecular model building of Electron Cryo‐microscopy and Crystallographic DataProtein Science, 2019
- A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein‐bound drugs and the impact of errors in plasma protein bindingBiopharmaceutics & Drug Disposition, 2015
- Addressing phototoxicity observed in a novel series of biaryl derivatives: Discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436Bioorganic & Medicinal Chemistry, 2015
- Volume of Distribution in Drug DesignJournal of Medicinal Chemistry, 2015
- Managing the challenge of chemically reactive metabolites in drug developmentNature Reviews Drug Discovery, 2011
- Toll-like Receptor 7 and TLR9 Dictate Autoantibody Specificity and Have Opposing Inflammatory and Regulatory Roles in a Murine Model of LupusImmunity, 2006
- Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cellsEuropean Journal of Immunology, 2003
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- A Toll-like receptor recognizes bacterial DNANature, 2000